Brawn Biotech

Which are the latest news on Brawn Biotech?

Why is Brawn Biotech Ltd falling/rising?

As of 05-Sep, Brawn Biotech Ltd's stock price is rising to 22.70, reflecting a 0.44% increase and a total return of 0.89% over the last two days. The stock has outperformed the Sensex over the past month, and increased investor interest is indicated by a significant rise in delivery volume.

As of 05-Sep, Brawn Biotech Ltd's stock price is rising, currently at 22.70, with a change of 0.1 (0.44%) upward. This increase follows a trend where the stock has gained for the last two days, resulting in a total return of 0.89% during this period. Additionally, the stock has shown positive performance over the past month, with a 3.23% increase, contrasting with the Sensex, which has decreased by 2.44% in the same timeframe. <BR><BR>Investor participation appears to be increasing, as evidenced by a significant rise in delivery volume, which was 710 on September 3, marking a 95.92% increase compared to the 5-day average. This suggests growing interest in the stock. Furthermore, the current price is above the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend in the stock's performance. <BR><BR>Despite underperforming its sector by 0.83% today, the overall upward movement in price and increased investor activity contribute to the stock's rising trajectory.

Who are in the management team of Brawn Biotech?

The management team of Brawn Biotech consists of B R Gupta (Chairman & Managing Director), Brij Bala Gupta (Director), Subhash Chander (Independent Director), Kanta Takkar (Independent Director), and Priyanka Sharma (Company Secretary).

The management team of Brawn Biotech includes the following individuals:<BR><BR>1. B R Gupta - Chairman & Managing Director<BR>2. Brij Bala Gupta - Director<BR>3. Subhash Chander - Independent Director<BR>4. Kanta Takkar - Independent Director<BR>5. Priyanka Sharma - Company Secretary<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Brawn Biotech do?

Brawn Biotech Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 6 Cr and a net profit of 0 Cr for June 2026. The company has a market cap of INR 7 Cr and key metrics include a P/E of 8.00 and a return on equity of 22.97%.

Overview: <BR>Brawn Biotech Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Brawn Biotech Limited was originally incorporated as Brawn Pharmaceuticals Limited in November 1985. The company changed its name to Brawn Biotech Limited in November 2010. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 6 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 22.97% <BR>Price to Book: 1.94 <BR><BR>Contact Details: <BR>Address: C-64 Lajpat Nagar-1 1st Floor, New Delhi, New Delhi: 110024 <BR>Email: solution@brawnpharma.com <BR>Website: http://www.brawnbiotech.com

Who are the peers of the Brawn Biotech?

Brawn Biotech's peers include Unjha Formul., Ortin Global, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, Fabino Enter, and Shyama Computro. Unjha Formul. shows the best management and growth metrics, while Brawn Biotech has average management risk and a 1-year return of -2.74%.

Peers: The peers of Brawn Biotech are Unjha Formul., Ortin Global, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, Fabino Enter, and Shyama Computro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Average management risk is found at Brawn Biotech and the rest. Below Average management risk is noted for Ortin Global, Beryl Drugs, Ganga Pharma., Vivanza Biosci., Decipher Labs, and Fabino Enter. Growth is Below Average for Brawn Biotech, Ortin Global, Beryl Drugs, Ganga Pharma., Decipher Labs, and Fabino Enter, while Vivanza Biosci. has Average growth. Capital Structure is Good at Unjha Formul., Average at Ganga Pharma., and Below Average for Brawn Biotech, Ortin Global, Beryl Drugs, Vivanza Biosci., Decipher Labs, and Fabino Enter.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 10.70%, while Decipher Labs has the lowest at -48.50%. Brawn Biotech's 1-year return is -2.74%, which is better than Decipher Labs but worse than Unjha Formul. Additionally, the six-month returns are negative for Ortin Global, Vivanza Biosci., Decipher Labs, and Shyama Computro.

How big is Brawn Biotech?

As of 31st August, Brawn Biotech Ltd has a market capitalization of 7.00 Cr, with recent net sales of 0.36 Cr and a net profit of 0.21 Cr. Shareholder's funds are 3.36 Cr, and total assets amount to 19.97 Cr as of March 2025.

As of 31st August, Brawn Biotech Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Brawn Biotech reported Net Sales of 0.36 Cr and a Net Profit of 0.21 Cr. <BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 3.36 Cr and Total Assets of 19.97 Cr.

Should I buy, sell or hold Brawn Biotech Ltd?

When is the next results date for Brawn Biotech Ltd?

The next results date for Brawn Biotech Ltd is 13 August 2026.

The next results date for Brawn Biotech Ltd is scheduled for 13 August 2026.

Are Brawn Biotech Ltd latest results good or bad?

Brawn Biotech Ltd's latest results are concerning, showing a net loss of ₹0.04 crores in Q2 FY26, a 117.39% decline in profitability from the previous quarter, stagnant revenue, and deteriorating operating margins, indicating significant operational challenges and a troubling financial outlook.

Brawn Biotech Ltd's latest results indicate a troubling financial situation. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant decline from a profit of ₹0.23 crores in the previous quarter, marking a dramatic 117.39% drop in profitability. Revenue remained stagnant at ₹0.12 crores, unchanged from the prior quarter, highlighting severe challenges in business momentum.<BR><BR>The operating margin has also deteriorated sharply, falling to -33.33% from a positive 25.0% in Q1 FY26. This indicates significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity stands at a concerning -16.49%, reflecting the company's struggle to generate positive returns for shareholders.<BR><BR>Over the past five years, Brawn Biotech has seen its annual revenues plummet by 73.47%, raising fundamental concerns about the viability of its business model. The company's financial trajectory is characterized by persistent losses, minimal revenue growth, and a lack of institutional interest, which further complicates its outlook.<BR><BR>In summary, the latest results are indicative of a deteriorating financial condition, with multiple red flags suggesting that the company is facing significant operational and structural challenges.

How has been the historical performance of Brawn Biotech?

As of March 2023, Brawn Biotech reported net sales and total operating income of 0.48 crore, with a profit after tax of 0.19 crore and a PAT margin of 39.58%. The company has total assets and liabilities of 14.37 crore each, no debt, and stagnant cash flow, indicating limited operational activity and a need for revenue growth.

Answer:<BR>The historical performance of Brawn Biotech shows a modest financial position as of March 2023, with net sales reported at 0.48 crore and total operating income also at 0.48 crore. The company incurred total expenditure of 0.48 crore, resulting in an operating profit (PBDIT) of 0.24 crore after accounting for other income. The profit before tax stood at 0.22 crore, leading to a profit after tax of 0.19 crore, which translates to a PAT margin of 39.58%. The earnings per share (EPS) were recorded at 0.39, while the diluted EPS was slightly lower at 0.38. <BR><BR>In terms of assets and liabilities, Brawn Biotech's total assets as of March 2023 were 14.37 crore, with total liabilities at 14.37 crore, indicating a balanced sheet with no debt. The company's shareholder's funds were 6.31 crore, and the book value per share adjusted was 21.03. The cash flow results indicate that the company had no cash inflow or outflow from operating, investing, or financing activities, reflecting a stagnant cash position over the years. Overall, Brawn Biotech's financials suggest a company with limited operational activity and a need for growth in revenue generation. <BR><BR>Breakdown:<BR>Brawn Biotech's financial performance as of March 2023 reveals net sales of 0.48 crore, with total operating income matching this figure. The company faced total expenditures of 0.48 crore, leading to an operating profit of 0.24 crore, bolstered by other income. The profit before tax was 0.22 crore, resulting in a profit after tax of 0.19 crore, which corresponds to a PAT margin of 39.58%. The earnings per share were 0.39, while the diluted EPS was slightly lower at 0.38. On the balance sheet, total assets and liabilities were both at 14.37 crore, with shareholder's funds at 6.31 crore and a book value per share of 21.03. The cash flow statements indicate no activity in cash inflows or outflows, suggesting a lack of operational movement in the company's financial activities.

Is Brawn Biotech overvalued or undervalued?

As of June 11, 2024, Brawn Biotech is considered risky and overvalued due to its negative PE ratio of -2.75, poor financial metrics compared to peers, and a year-to-date stock performance decline of -23.04%.

As of 11 June 2024, Brawn Biotech's valuation grade has moved from does not qualify to risky, indicating a significant change in its perceived financial health. The company appears to be overvalued given its negative PE ratio of -2.75, an EV to EBIT of -2.48, and a ROCE of -47.62%. These ratios highlight the company's struggles in generating profits and returns on capital.<BR><BR>In comparison to its peers, Brawn Biotech's financial metrics stand out unfavorably. For instance, MMTC has a PE ratio of 119.39, while PTC India boasts a much more attractive PE of 9.02, showcasing the stark contrast in valuation within the industry. Additionally, Brawn Biotech's recent stock performance has been poor, with a year-to-date return of -23.04% compared to the Sensex's positive return of 5.58%, reinforcing the notion that the company is overvalued in its current state.

What is the technical trend for Brawn Biotech?

As of June 3, 2025, Brawn Biotech's trend has shifted to bearish with moderate strength, driven by daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST, and a year-to-date return of -19.29% compared to the Sensex's 5.51% gain.

As of 3 June 2025, the technical trend for Brawn Biotech has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating a bearish trend, and both the weekly and monthly Bollinger Bands confirming a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, indicating mixed signals. The KST is also mildly bullish weekly but bearish monthly, adding to the overall bearish sentiment. The stock's performance has been weak, with a year-to-date return of -19.29%, contrasting with the Sensex's positive return of 5.51%.

Who are the top shareholders of the Brawn Biotech?

The top shareholders of Brawn Biotech are primarily promoters, with Brij Raj Gupta holding the largest stake at 16.69%. Individual investors own 33.17% of the shares, while the highest public shareholder is Daksha Kotak at 1.24%.

The top shareholders of Brawn Biotech primarily include the promoters, with Brij Raj Gupta holding the largest individual stake at 16.69%. Additionally, individual investors collectively own 33.17% of the shares. The company has no pledged promoter holdings, and there are no foreign institutional investors (FIIs) involved. The highest public shareholder is Daksha Kotak, who holds 1.24%. Overall, the majority of the shares are held by the promoters.

Has Brawn Biotech declared dividend?

Brawn Biotech Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 12, 2018. However, the company has shown significant losses over various periods, resulting in a consistent dividend yield of 0% in recent times.

Brawn Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 12 Sep 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -25.42%, the dividend return was 0%, resulting in a total return of -25.42%.<BR><BR>In the 1 year period, the price return was -37.33%, the dividend return was 0%, resulting in a total return of -37.33%.<BR><BR>In the 2 years period, the price return was 1.23%, the dividend return was 0%, resulting in a total return of 1.23%.<BR><BR>In the 3 years period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4 years period, the price return was -50.3%, the dividend return was 0%, resulting in a total return of -50.3%.<BR><BR>In the 5 years period, the price return was -40.15%, the dividend return was 0%, resulting in a total return of -40.15%.<BR><BR>Overall, while Brawn Biotech has declared a dividend, the total returns over various periods indicate significant losses, particularly in the longer term, suggesting challenges in the company's financial performance. The consistent dividend yield of 0% in recent periods further reflects a lack of ongoing dividend distributions.